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Abstract. Immunotherapy is one of the attractive treatment 
strategies for advanced prostate cancer. The US Food and 
Drug Administration (FDA) previously approved the thera-
peutic vaccine, sipuleucel-T, which is composed of autologous 
antigen-presenting cells cultured with a fusion protein [pros-
tatic acid phosphatase (PAP) and granulocyte-macrophage 
colony-stimulating factor (GMCSF)]. Although sipuleucel-T 
has been shown to prolong the median survival of patients for 
4.1 months, more robust therapeutic effects may be expected 
by modifying the vaccination protocol. In the present study, 
we aimed to develop and validate a novel vaccination strategy 
using multiple PAP-fused cytokines for prostate cancer treat-
ment. Using a super gene expression (SGE) system that we 
previously established to amplify the production of a recom-
binant protein, significant amounts of PAP-fused cytokines 
[human GMCSF, interleukin-2 (IL2), IL4, IL7 and mouse 
GMCSF and IL4] were obtained. We examined the activity of 
the fusion proteins in vitro to validate their cytokine functions. 
A significant upregulation of dendritic cell differentiation 
from monocytes was achieved by PAP-GMCSF when used 
with the other PAP-fused cytokines. The PAP-fused human 
IL2 significantly increased the proliferation of lymphocytes, 
as determined by flow cytometry. We also investigated the 
in vivo therapeutic effects of multiple PAP-fused cytokines 
in a mouse prostate cancer model bearing prostate-specific 
antigen (PSA)- and PAP-expressing tumors. The simultaneous 
intraperitoneal administration of PAP-GMCSF, -IL2, -IL4 
and -IL7 significantly prevented tumor induction and inhibited 
the tumor growth in the PAP-expressing tumors, yet not in the 
PSA-expressing tumors. The in vivo therapeutic effects with 
the multiple PAP-fused cytokines were superior to the effects 
of PAP-GMCSF alone. We thus demonstrated the advantages 
of the combined use of multiple PAP-fused cytokines including 
PAP-GMCSF, and propose a promising prostatic antigen-
vaccination strategy to enhance the therapeutic effects.
Introduction
Prostate cancer is a commonly diagnosed malignant disease 
in males worldwide, and there are no effective treatment 
options once the cancer becomes metastatic and refractory 
to hormonal therapy and chemotherapy. In prostatic tissues, 
including both the normal prostate and prostate cancer, the 
expression of several specific proteins, such as prostate-
specific antigen (PSA), prostate-specific membrane antigen 
(PSMA), prostatic acid phosphatase (PAP) and prostate 
secretory protein-94 (PSP94) has been described (1-3). By 
targeting these prostate-specific proteins to establish anti-
tumor vaccines, immunotherapy has been developed, and has 
recently been suggested to have potential for the treatment of 
prostate cancer (4-7).
PAP is a secretory prostate-specific protein that consists 
of 354 amino acids with an estimated molecular mass of 
41 kDa (1,2). Homologs of the human PAP gene have been 
identified in rats and mice, and these proteins respectively 
share 75 and 81% homology with the human protein at the 
amino acid level (2). PAP is overexpressed in 95% of prostate 
cancer tissues (8), and the tissue specificity of PAP makes it 
an attractive target antigen for immunotherapy against pros-
tatic malignancy (8,9). Several vaccine candidates have been 
developed based on the PAP protein using cell-based medi-
cine (10,11), DNA vaccines (12) or peptide antigens (13,14).
Using the full-length PAP protein as a vaccine target, 
sipuleucel-T (Provenge®; Dendreon Inc., Seattle, WA, USA), 
an autologous active cellular immunotherapy, was developed 
for the treatment of metastatic castration-resistant prostate 
cancer (10). The cellular agent is manufactured from indi-
vidual peripheral monocytes enriched by leukapheresis, and 
is an antigen-presenting cell vaccine loaded ex vivo with 
a fusion protein linking PAP to granulocyte-macrophage 
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colony-stimulating factor (GMCSF) (15,16). After incubation 
with the PAP-GMCSF fusion protein, the immunologically 
activated cells are intravenously administered to patients every 
two weeks for a total of three infusions. A placebo-controlled 
randomized phase III trial demonstrated that the personalized 
cell-based vaccine showed evidence of efficacy in reducing 
the risk of death among patients with prostate cancer refrac-
tory to hormonal therapy (10). In the patients treated with 
sipuleucel-T, there was a relative reduction of 22% in the risk 
of death compared with the placebo group, representing a 
4.1-month improvement in median survival (25.8 months in 
the sipuleucel-T group vs. 21.7 months in the placebo group). 
Based on the results of a phase III study, the US Food and 
Drug Administration (FDA) approved sipuleucel-T for the 
treatment of prostate cancer in April 2010, and this was the 
first antigen-specific immunotherapy officially approved in a 
developed country.
Although sipuleucel-T can prolong the overall survival in 
patients with progressive prostate cancer, more robust immuno-
logical effects seem to be possible that can further improve 
survival. In order to enhance the therapeutic effects of the 
PAP-GMCSF fusion protein, we experimentally tried to modify 
the methods and to develop a novel vaccination strategy with 
the additional use of multiple PAP-fused cytokines, including 
human interleukin-2 (IL2), IL4 and IL7. The reason for adding 
these interleukins is that these cytokines can potently activate 
anticancer immune cells and upregulate the effects of the thera-
peutic vaccination for cancer treatment (17-19).
The cost for sipuleucel-T is reported to be 93,000 US$ per 
course of treatment, thus making this therapeutic vaccine an 
expensive treatment option (11). One of the ways to reduce the 
pharmacological cost is to increase the production efficiency 
of the PAP-GMCSF fusion protein. Since we previously estab-
lished a super gene expression (SGE) cassette to amplify the 
production of a recombinant protein in 293-F cells (20,21), we 
herein attempted to apply this mammalian expression system 
to produce multiple PAP-fused cytokines. In the present study, 
we validated the activity of the PAP-fused proteins as cyto-
kines and demonstrated the advantages of the combined use of 
multiple PAP-fused cytokines in in vitro and in vivo situations.
Materials and methods
Construction of the SGE plasmid vectors encoding PAP-fused 
cytokines. The construction of a plasmid vector with the SGE 
system was performed as previously described (20,21). The 
gene expression cassette with the CMV promoter, sequences 
of RU5', bovine growth hormone polyadenine nucleotides 
(BGH polyA) and tandem elements of triple translational 
enhancers hTERT, SV40 and CMV was artificially synthe-
sized and cloned into the pIDT-SMART vector (Integrated 
DNA Technologies, Inc., Coralville, IA, USA) (Fig. 1A). The 
RU5' sequence [269 bp, accession no. j02029 (374-642)] was 
derived from the R segment and part of the U5 sequence of the 
HTLV type 1 long terminal repeat and was used to enhance 
the stability of DNA and RNA and increase the translation 
efficiency (21). The tandem element of the triple translational 
enhancers consists of the hTERT enhancer [189 bp, accession 
no. DQ264729 (1618-1806)], SV40 enhancer [319 bp, acces-
sion no. AY864928 (2156-2474)] and CMV enhancer [479 bp, 
accession no. Aj318513 (159-637)]. The tandem sequence of 
the hTERT, SV40 and CMV enhancers is the main element 
of the SGE system. The SGE plasmid encoding a fusion 
protein of full-length human PAP and one of the cytokines 
(human GMCSF, IL2, IL4, IL7 or mouse GMCSF or IL4) 
were then constructed and used to express the recombinant 
PAP-fused cytokines. The fusion cytokines were designed to 
be histidine-tagged for purification.
Preparation of the recombinant PAP-fused cytokines. The 
recombinant PAP-fused cytokines were expressed by the 
FreeStyle 293 expression system (Invitrogen, Carlsbad, CA, 
USA) with the respective SGE plasmids according to the 
manufacturer's instructions. The expression system was 
designed to allow the transfection of suspended 293-F cells 
(derived from HEK293 cells) in serum-free culture medium. 
Transient transfection with the plasmid vector was performed, 
and the secreted recombinant fusion protein in the culture 
supernatant was collected. The PAP-fused cytokines were 
purified using the histidine tag included in the fusion protein, 
as previously described (22). The recombinant PAP-fused 
cytokines were stocked and maintained at -80˚C until use. 
The PAP-fused human and mouse cytokines were analyzed 
for the protein amount, purity and concentration by examining 
the densitometry of the bands on SDS-PAGE with Coomassie 
brilliant blue (CBB) staining.
Preparation and culture conditions of blood mononuclear 
cells. Human peripheral blood mononuclear cells (PBMCs) 
were prepared from the blood of healthy donors by the standard 
procedure using Ficoll-Paque centrifugation (22). This research 
was carried out on humans following the international and 
national regulations. Written informed consent was obtained 
from the subjects. For some experiments, human CD14-
positive monocytes were purchased from Lonza (Walkersville, 
MD, USA). Mouse blood was obtained from the inferior vena 
cava, and the mononuclear cells were prepared by Ficoll-Paque 
centrifugation. The blood mononuclear cells and CD14-
positive monocytes were cultured either in LGM-3 medium 
(Lonza) alone or in the presence of recombinant PAP-fused 
cytokines under the indicated conditions. As a positive control 
for the differentiation of human dendritic cells, the PBMCs and 
CD14-positive monocytes were cultured in LGM-3 medium 
supplemented with human granulocyte-macrophage colony-
stimulating factor (hGMCSF; 2 ng/ml) and human interleukin-4 
(hIL4; 2 ng/ml) (both from R&D Systems, Minneapolis, MN, 
USA) (17,22). The cells were cultured at 37˚C in humidified 
incubators containing air with 5% CO2.
Proliferation assay using TF-1 cells. TF-1, a human GMCSF-
dependent proliferative cell line (23,24), was used to analyze 
the cytokine activity of PAP-hGMCSF. TF-1 cells (104 cells/
well) were plated on 96-well plates and cultured as previously 
reported (23). The PAP-hGMCSF was added to the culture 
medium at the indicated concentrations derived from a 3-fold 
serial dilution. hGMCSF was used as a positive control for the 
GMCSF-dependent proliferation. After three days of incuba-
tion, the proliferation of the TF-1 cells was analyzed with the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay, according to the manufacturer's instructions.
ONCOLOGY REPORTS  33:  1585-1592,  2015 1587
Flow cytometric analysis. To analyze the proliferation of 
CD8+, CD4+ and CD19+ lymphocytes, flow cytometry was 
performed as previously described (22). Human PBMCs 
(75x104 cells/well) were incubated with PAP-hIL2 (1 µg/ml) 
for four days on 6-well plates, and then the floating cells were 
examined for each surface antigen. The cells were stained 
with the following FITC-conjugated antibodies for 60 min on 
ice: CD8 (551347; BD Pharmingen, San Diego, CA, USA) as a 
marker for cytotoxic T lymphocytes, CD4 (555346) for helper 
T lymphocytes and CD19 (555412) for B lymphocytes. After 
staining, 2x104 cells were acquired on a FACSCalibur flow 
cytometer and analyzed using the CellQuest software program 
(both from Becton-Dickinson, Franklin Lakes, Nj, USA).
Animal experiments. The RM9 mouse prostate cancer cell line 
was kindly provided by Dr T.C. Thompson (The University 
of Texas, Houston, TX, USA) (25) and was used in the 
animal experiments. In our experimental set-up, we prepared 
PSA-RM9 and PAP-RM9 cells stably expressing the human 
PSA or PAP protein, respectively. The stable clones of RM9 
cells were established by the transfection of plasmids encoding 
the full-length human PSA or PAP genes and a neomycin-
resistance gene, as previously described (20,21,26). Using 
the PSA-RM9 and PAP-RM9 cells, we developed a mouse 
prostate cancer model bearing both PSA- and PAP-expressing 
tumors. The in vivo experimental schedule and treatments 
with the PAP-fused cytokines are shown in Fig. 4A. Since IL2 
and IL7 possess cross-reactivity between human and mouse 
species (27-29), we used PAP-human IL2 and PAP-human IL7 
instead of PAP-mouse IL2 and PAP-mouse IL7, respectively. A 
total of nine intraperitoneal administrations of the PAP-fused 
cytokines were performed. On day 7, the PSA-RM9 and 
PAP-RM9 cells were subcutaneously inoculated into the left 
and right femurs, respectively, of C57BL/6 adult male mice. 
All mice were examined for the tumor formation and for 
the tumor size on day 21, and then were sacrificed. Animal 
experiments using anticancer cytokines were approved by the 
Animal Care and Use Committee, Okayama University.
Statistical analysis. The data are expressed as the means ± stan-
dard error. Student's t-test or the Chi-square test was used to 
determine the statistical significance of differences between 
the two groups. Differences were considered to be statistically 
significant for values of p<0.05.
Results
Production of recombinant multiple PAP-fused cytokines using 
the SGE system. We previously developed the SGE system in 
order to improve the protein production by conventional gene 
expression systems (20,21). In the gene expression cassette with 
the SGE system, triple translational enhancer sequences of 
hTERT, SV40 and the CMV enhancer were inserted downstream 
of the BGH polyA sequence (Fig. 1A). We recently reported that 
the SGE system significantly enhanced adenoviral vector-medi-
ated gene expression (~2- to 5-fold) in human cancer cell lines, 
as determined by western blot analysis) in comparison to the 
system using conventional gene expression (20). Therefore, we 
herein attempted to apply this mammalian expression system to 
produce the multiple PAP-fused cytokines.
The amount of protein produced and the purity of the 
recombinant PAP-fused cytokines produced by the SGE system 
Figure 1. (A) A schematic diagram of the super gene expression (SGE) system. In this SGE system, triple translational enhancer sequences of hTERT, SV40 
and the CMV enhancer were inserted downstream of the BGH polyA sequence. (B) PAP-fused human (h) or mouse (m) cytokines were produced by the 
SGE system in the 293-F cells with serum-free culture medium. To examine the amount and purity of the recombinant PAP-fused cytokines in the medium, 
the supernatant on day 5 after transfection was analyzed by SDS-PAGE with Coomassie brilliant blue (CBB) staining. BGH polyA, bovine growth hormone 
polyadenine nucleotides.
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were analyzed by SDS-PAGE with CBB staining (Fig. 1B). 
As a result, a significant amount of PAP-fused cytokines was 
obtained in the serum-free culture medium of the 293-F cells 
on day 5 by the transient gene expression. The recombinant 
fusion proteins were recognized as single bands by gel elec-
trophoresis. The concentration (mg/l) of the fusion proteins in 
the medium was calculated: PAP-hGMCSF, 123.3; PAP-hIL2, 
91.7; PAP-hIL4, 96.9; PAP-hIL7, 64.5; PAP-mGMCSF, 94.2; 
PAP-mIL4, 62.8.
Recombinant PAP-fused cytokines maintain their cytokine 
activity. In order to confirm the cytokine activity of the 
recombinant PAP-fused cytokines, we conducted in vitro 
experiments with PAP-hGMCSF and PAP-hIL2. It is known 
that human GMCSF stimulates the proliferation of TF-1 
cells (23,24). Therefore, we first analyzed the growth depen-
dency of TF-1 cells by adding PAP-hGMCSF in the culture 
medium. The cell proliferation at the indicated concentrations 
was assessed by determining the absorbance of the cells in 
the MTT assay. The results indicated that proliferation of 
the TF-1 cells was increased in a dose-dependent manner by 
PAP-hGMCSF (Fig. 2A). We next investigated the IL2 activity 
of PAP-hIL2 by evaluating the proliferation of lymphocyte 
lineages. The cultivation of human PBMCs in the presence of 
PAP-hIL2 resulted in the rapid growth of the CD8+, CD4+ and 
CD19+ lymphocytes within four days, as determined by flow 
cytometry (Fig. 2B). These results indicate that the recombi-
nant PAP-fused cytokines produced by the SGE system retain 
the usual cytokine activity.
Differentiation of dendritic cells is enhanced by the combined 
use of multiple PAP-fused cytokines, including PAP-GMCSF. 
To confirm the ability of the multiple PAP-fused cytokines to 
induce the differentiation of monocytes into dendritic cells, 
purified monocytes from PBMCs were cultured in the pres-
ence of recombinant fusion cytokines. Since GMCSF has been 
considered to be an essential cytokine for the differentiation 
and maturation of dendritic cells (17), we basically used 
PAP-GMCSF and attempted to combine the other PAP-fused 
cytokines with it in order to augment the immunological 
effects. During the first two days of treatment with the multiple 
PAP-fused cytokines (including PAP-hGMCSF), most of the 
monocytes displayed cellular elongation (Fig. 3A). The ratio 
of elongated monocytes in samples treated with the multiple 
fusion cytokines was higher than that in the cells treated with 
PAP-hGMCSF alone. With regard to the monocytes culti-
vated with medium alone, there were only a few cells with 
dendritic-cell like features.
We next quantified the dendritic cell differentiation induced 
by the treatment with multiple PAP-fused cytokines, including 
PAP-GMCSF. Since it has been well established that dendritic 
cells can be differentiated by incubation with GMCSF and 
IL-4 (17,22), we referred to the morphological features of cells 
treated with these cytokines as a positive control for dendritic 
cells (Fig. 3B). After the incubation with PAP-fused human 
cytokines, the number of cells developing into human dendritic 
cells was counted in several microscopic fields. When treated 
with the multiple fused cytokines, the number of developing 
dendritic cells was significantly increased in comparison to 
those treated with PAP-GMCSF alone (Fig. 3C). The enhanced 
differentiation of mouse dendritic cells was also confirmed by 
cultivating the blood mononuclear cells with multiple fusion 
cytokines, including PAP-mGMCSF and PAP-mIL4 (Fig. 3D). 
These results indicated that the differentiation of dendritic 
cells was enhanced by the combined use of multiple PAP-fused 
cytokines, including PAP-GMCSF.
In vivo therapeutic effects are enhanced by the combined use 
of multiple PAP-fused cytokines, including PAP-GMCSF. The 
in vitro results in the present study indicated the possibility that 
a PAP-fused cytokine-based in vivo increase in immune cells 
may upregulate the anticancer immune response by targeting 
the PAP molecule. In order to investigate the antitumor effects 
of PAP-fused cytokines, in vivo experiments were performed 
using a mouse prostate cancer model bearing both PSA- and 
PAP-expressing tumors (Fig. 4A). As a PAP-targeting vaccine, 
the multiple PAP-fused cytokine treatment would be expected 
to be most effective for use against the initial stages of pros-
tate cancer or for minimal disease. Therefore, the vaccine was 
started to be administered before the cancer cell inoculation in 
our preclinical mouse model.
In the preliminary experiments, in vitro and in vivo stable 
expression of the PSA and PAP proteins was confirmed for the 
PSA-RM9 and PAP-RM9 cells, respectively (data not shown). 
Since IL2 and IL7 possess cross-reactivity between humans 
and mice (27-29), we used PAP-human IL2 and PAP-human 
IL7 instead of PAP-mouse IL2 and PAP-mouse IL7, respec-
tively. We first analyzed whether the PAP-fused cytokines 
could protect mice against challenge with a PAP-expressing 
tumor. The incidence of PSA-RM9 and PAP-RM9 tumor 
formation was analyzed on day 21 after the subcutaneous inoc-
ulation of cancer cells. In the present study, PSA-expressing 
Figure 2. (A) Growth dependency of TF-1 cells on human (h)GMCSF and 
PAP-hGMCSF was analyzed. The cell proliferation at the indicated concen-
trations was assayed by determining the absorbance at 570 nm in the MTT 
assay. (B) Proliferation of CD8+, CD4+ and CD19+ lymphocytes following 
treatment with PAP-hIL2 was analyzed by flow cytometry. Human peripheral 
blood mononuclear cells (PBMCs) were incubated with PAP-hIL2 (1 µg/ml) 
for four days, and then the floating cells were examined for each surface 
antigen. GMCSF, granulocyte-macrophage colony-stimulating factor.
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tumors derived from PSA-RM9 cells were monitored for 
the effects of the PAP-based immunological treatments. 
The co-administration of PAP-GMCSF, -IL2, -IL4 and -IL7 
significantly prevented the tumor induction of PAP-RM9 
cancer cells (Fig. 4B). On the other hand, the treatment with 
PAP-GMCSF alone failed to prevent the tumor formation.
We next investigated whether PAP-fused cytokines 
inhibits PAP-RM9 tumor growth in vivo. Significant inhibi-
tion of the tumor growth was observed in the groups treated 
with both PAP-GMCSF alone and with the co-administration 
of PAP-GMCSF, -IL2, -IL4 and -IL7 (Fig. 4C). The in vivo 
therapeutic effects of the multiple PAP-fused cytokines were 
superior to the effects observed with PAP-GMCSF treatment 
alone. For the control PSA-expressing tumors derived from 
PSA-RM9 cells, no significant therapeutic effect was observed 
following the treatments with PAP-fused cytokines. Based on 
the results of the tumor challenge and growth, it was concluded 
that PAP-specific immune activation occurred in the mice 
treated with the PAP-fused cytokines, and the antitumor 
effects were significantly enhanced by the additional cytokine 
(IL2, IL4 and IL7) fusion proteins.
Discussion
In the present study, we experimentally validated a 
PAP-GMCSF-based vaccine strategy with multiple PAP-fused 
cytokines for the immunotherapy of prostate cancer. We 
also demonstrated the availability of the SGE system for the 
production of recombinant PAP-fused cytokines. With regard 
to the SGE system, we originally developed it as a gene expres-
sion system that allows the gene of interest to be expressed 
with very high efficiency in 293-F cells (20,21). In this SGE 
construct of the vectors, the linkage of triple translational 
enhancer sequences of hTERT, SV40 and CMV enhancers 
was inserted into a site downstream of the sequence of the 
BGH polyA. The CMV promoter driving SGE system robustly 
enhanced the gene expression of plasmid and adenoviral 
vectors in comparison to the cassette with CMV promoter 
alone (20). The superiority of the CMV promoter-SGE system 
was also observed compared to the gene expression cassette 
with EF-1α and CAG promoters alone (21). Using this SGE 
system, we succeeded in producing a significant amount of 
the PAP-fused cytokines (human GMCSF, IL2, IL4, IL7, and 
mouse GMCSF and IL4) in the medium of 293-F cells. The 
recombinant proteins were easily concentrated for use in the 
experiments and demonstrated activity as cytokines.
We herein examined the activity of the fusion proteins as 
cytokines in vitro, and significant upregulation of dendritic 
cell differentiation from monocytes was achieved by treat-
ment with PAP-GMCSF when it was used with the other 
PAP-fused cytokines. The PAP-fused human IL2 led to 
significantly increased proliferation of T and B lymphocytes, 
Figure 3. (A) Appearance of human CD14-positive monocytes developing into dendritic cells was evaluated. For the treatments, each PAP-fused human 
cytokine was added at a concentration of 1 µg/ml. The morphology of the cells on day 1 was photographed under a phase contrast microscope. (B) The appear-
ance of human dendritic cells (arrow) differentiated from peripheral blood mononuclear cells (PBMCs) is shown. The dendritic cells were induced by the 
incubation with hGMCSF and hIL4 (each, 2 ng/ml) for seven days. The morphology of the cells on day 7 was photographed under a phase contrast microscope. 
(C) Differentiation of human dendritic cells was quantified for the different treatment groups. The monocytes were treated with hGMCSF and hIL4 (each, 
2 ng/ml) or with the PAP-fused cytokines (each, 1 µg/ml) for three days. The number of cells developing into dendritic cells was counted for five randomly 
selected fields under a microscope, and the results are shown. *Significant difference was observed in comparison to the treatment with hGMCSF and hIL4. 
**Significant difference was observed in comparison to the treatment with PAP-hGMCSF alone. (D) Differentiation of mouse dendritic cells was quantified for 
the different treatment groups. The blood mononuclear cells were treated with PAP-fused mouse (m) cytokines (each, 5 µg/ml) for seven days. The number of 
cells developing into dendritic cells was counted for five randomly selected fields under a microscope, and the results are shown. *Significant difference was 
observed in comparison to the mononuclear cells treated with medium alone. hGMCSF, human granulocyte-macrophage colony-stimulating factor.
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as determined by flow cytometry. We thus validated the cyto-
kine functions of the PAP-fused cytokines. Dendritic cells are 
antigen-presenting cells that play important roles in anticancer 
immune responses. GMCSF has been considered to be the 
main cytokine required for the differentiation and maturation 
of dendritic cells (17). The combined use of GMCSF and IL4 
is the most extensively characterized and utilized combination 
for the in vitro differentiation of dendritic cells from periph-
eral blood monocytes (17,22). In terms of the effects of the 
different cytokine combinations with GMCSF on the develop-
ment of dendritic cells, the addition of IL2 and IL7 also plays 
important roles (17,30-32). Moreover, previous reports indicate 
that IL2 induces the differentiation and/or maturation toward 
a dendritic cell phenotype without GMCSF (31), and could 
enhance the motility of dendritic cells (30).
With regard to the other immune cells (other than antigen-
presenting cells), CD4+ and CD8+ T lymphocytes, CD19+ 
B lymphocytes and natural killer (NK) cells all play important 
roles in antitumor immunity. Interleukins, including IL2, 
IL4 and IL7, are known to exhibit and enhance antitumor 
effects, not only through the activation of these antitumor 
immune cells, yet also via the activation of macrophages and 
lymphokine-activated killer (LAK) cells (3,33-35). Thus, as a 
result of the enhanced cancer-specific immunity following the 
simultaneous activation of these immune cells, the combined 
use of multiple cytokines is a promising strategy (Fig. 5). Our 
results also indicate that this strategy could be adaptable for 
Figure 4. (A) In vivo experimental schedule and treatments with PAP-fused cytokines are shown. (A-C) Treatments were performed intraperitoneally and 
the animals were separated into three groups. On day 7, mouse prostate cancer RM9 cells stably expressing human PSA and PAP (PSA-RM9 and PAP-RM9 
cells) were subcutaneously inoculated into the left and right femurs of C57BL/6 adult male mice, respectively. The PSA-expressing tumors derived from 
PSA-RM9 cells were monitored as a negative control for the PAP-based immunological treatments. All mice were examined for tumor formation and tumor 
size on day 21. PBS, phosphate-buffered saline. (B) Antitumor effects of the treatment are shown with regard to preventing tumor formation. The incidence 
of PSA-RM9 and PAP-RM9 tumor formation was analyzed on day 21. *Significant difference was observed in comparison to the tumor formation (%) of the 
PAP-RM9 in group A. (A-C) Each treatment group comprised five mice. (C) Antitumor effects of the treatments are shown with regard to the suppression of 
tumor growth. The PSA-RM9 and PAP-RM9 tumor sizes were analyzed on day 21. The values are represented as the percentages of the respective PSA-RM9 
or PAP-RM9 tumor sizes in group A. *Significant difference was observed in comparison to the tumor size of the PAP-RM9 tumors in group A. PSA, prostate-
specific antigen; PAP, prostatic acid phosphatase.
Figure 5. Ex vivo and in vivo vaccine strategy with multiple PAP-fused cyto-
kines for prostate cancer treatment. The combined use of multiple PAP-fused 
cytokines, including PAP-GMCSF, activated the anticancer immune cell 
lineages simultaneously. We propose that the therapeutic effects of the PAP-
fused cytokines were enhanced and superior to the effects with PAP-GMCSF 
alone. PAP, prostatic acid phosphatase; GMCSF, granulocyte-macrophage 
colony-stimulating factor.
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both ex vivo activation and in vivo activation of the immune 
cells for immunotherapy. Further studies are warranted toward 
the clinical application of the PAP-GMCSF-based vaccine 
strategy with multiple PAP-fused cytokines for prostate cancer 
treatment.
To further demonstrate the utility of the multiple PAP-fused 
cytokines, we investigated the in vivo therapeutic effects of 
the recombinant proteins in a mouse prostate cancer model 
bearing both PSA- and PAP-expressing tumors. The co-admin-
istration of PAP-GMCSF, -IL2, -IL4 and -IL7 significantly 
prevented tumor induction and inhibited tumor growth in the 
PAP-expressing tumors, yet not in the PSA-expressing tumors. 
The finding indicates that PAP-specific immune activation 
occurred in the mice treated with the PAP-fused cytokines. We 
also demonstrated that the tumor growth suppression by the 
multiple PAP-fused cytokines was superior to the effect with 
PAP-GMCSF alone. Therefore, the vaccination against PAP 
was significantly upregulated by the additional cytokine (IL2, 
IL4 and IL7) fusion proteins. The in vivo results are consistent 
with our in vitro findings showing the increased induction 
of dendritic cells and lymphocytes by the fusion cytokines. 
It is conceivable that the PAP-fused cytokines, including 
PAP-GMCSF, induced the robust differentiation of the mono-
cytes into antigen-presenting dendritic cells, resulting in the 
activation of PAP-specific CD4+ and CD8+ T lymphocytes 
in the treated mice. These activated T lymphocytes are then 
thought to work against the PAP-expressing tumor lesions in 
the mouse model, targeting the antigen and mediating the anti-
tumor responses. On the other hand, based on the increased 
induction of CD19+ B lymphocytes by the fusion cytokines 
in vitro, the antitumor effects could also be partially due to the 
humoral immunity of the PAP-specific antibodies induced in 
the mouse model.
A question that remains to be answered is associated 
with the peptide epitopes of the PAP antigen in the cellular 
arm of the immune response in the current C57BL/6 mouse 
model. Notably, other investigators recently reported that 
three human PAP epitopes (114-128, 299-313 and 230-244) 
were immunologically processed for vaccinations in mice (8). 
They demonstrated that the PAP (114-128) epitope, which is 
identical between human and mouse species at the amino 
acid level, elicits CD4+ and CD8+ T lymphocyte-specific 
responses in C57BL/6 mice. Furthermore, when adminis-
tered to mice bearing prostate cancer, the PAP (114-128) 
peptide prevented and reduced the growth of tumors in the 
prophylactic and therapeutic settings. These studies showed 
that the antitumor effects were associated with the infiltra-
tion of CD8+ tumor-infiltrating lymphocytes, and proposed 
that PAP (114-128) is a highly relevant peptide on which to 
base vaccines for the treatment of prostate cancer. Therefore, 
it is conceivable that the PAP epitopes, including the peptide 
(114-128), played essential roles in the anti-PAP vaccination 
processes in our mouse model after treatment. Additionally, 
we herein adopted a vaccination strategy using the full-length 
PAP protein as an immunogen. The use of entire proteins 
brings about significant advantages, since it can allow the 
immune cells to present multiple epitopes, including unknown 
epitopes associated with different MHC class I molecules, 
in addition to helper epitopes associated with MHC class II 
molecules (36).
The previously described therapeutic vaccine, sipuleucel-
T, is composed of autologous antigen-presenting cells cultured 
with a fusion protein of PAP-GMCSF, and its administration 
prolonged the overall survival among patients with metastatic 
castration-resistant prostate cancer (10). Sipuleucel-T has 
opened a new era for the treatment of prostate cancer (11), 
and immunotherapy has become one of the attractive treat-
ment strategies for various cancers. The immune responses 
to the immunized PAP antigen were augmented in patients 
who received sipuleucel-T (10), indicating that strategies 
that can enhance the effects of vaccination are attractive for 
the next step in immunotherapy. We herein demonstrated 
the advantages of the in vitro and in vivo combined use of 
multiple PAP-fused cytokines, including PAP-GMCSF, and 
therefore propose that the combined use of these fusion 
proteins could be promising for the enhancement of the 
immunological effects in prostatic antigen-based vaccination 
therapy. Moreover, if the super gene expression (SGE) system 
is applied in the Good Manufacturing Practice (GMP) setting, 
it could be used for the efficient production and cost-reduction 
of PAP-fused cytokines for clinical use. Further examinations 
will be required to apply the current strategy employing the 
PAP-fused cytokines for ex vivo and in vivo human immuno-
therapy.
In conclusion, we demonstrated the advantages of the 
combined use of multiple PAP-fused cytokines, including 
PAP-GMCSF, under in vitro and in vivo experimental condi-
tions, and propose that this prostatic antigen-based vaccination 
strategy should be promising for future clinical development. 
The current findings provide immunological insight for 
enhancing the therapeutic effects of cytokine-based immu-
notherapy. It should also be noted that the approach using 
multiple antigen-fused cytokines is adaptable to other cancer 
types by changing the prostatic PAP antigen to a different 
cancer-specific antigen.
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